Fulgent Genetics (NASDAQ:FLGT) and The Ensign Group (NASDAQ:ENSG) Head-To-Head Survey

Fulgent Genetics (NASDAQ:FLGT) and The Ensign Group (NASDAQ:ENSG) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.

Valuation & Earnings

This table compares Fulgent Genetics and The Ensign Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67 million	1.89	-$60.51 million	($2.82)	-7.86
The Ensign Group	$5.06 billion	1.98	$343.97 million	$6.38	26.95

The Ensign Group has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than The Ensign Group, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Fulgent Genetics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, The Ensign Group has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Fulgent Genetics and The Ensign Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1	2	1	0	2.00
The Ensign Group	0	2	4	0	2.67

Fulgent Genetics currently has a consensus price target of $27.50, suggesting a potential upside of 24.03%. The Ensign Group has a consensus price target of $216.25, suggesting a potential upside of 25.75%. Given The Ensign Group’s stronger consensus rating and higher probable upside, analysts clearly believe The Ensign Group is more favorable than Fulgent Genetics.

Insider & Institutional Ownership

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 96.1% of The Ensign Group shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 4.0% of The Ensign Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Fulgent Genetics and The Ensign Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
The Ensign Group	6.90%	16.75%	6.97%

Summary

The Ensign Group beats Fulgent Genetics on 12 of the 14 factors compared between the two stocks.

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

About The Ensign Group

The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The company's Skilled Services segment engages in the operation of skilled nursing facilities and rehabilitation therapy services for patients with chronic conditions, prolonged illness, and the elderly; and offers nursing facilities including specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management, as well as standard services comprising room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. Its Standard Bearer segment is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. In addition, the company provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. It operates in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.